Conv. Plasma
Nigella Sativa

All favipiravir studies
Meta analysis
study COVID-19 treatment researchFavipiravirFavipiravir (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 16% Improvement Relative Risk Ventilation 10% Favipiravir  Acar Sevinc et al.  ICU PATIENTS Is very late treatment with favipiravir beneficial for COVID-19? Retrospective 100 patients in Turkey (March - May 2020) Study compares with lopinavir/ritonavir, results vs. placebo may differ Lower mortality with favipiravir (not stat. sig., p=0.38) Acar Sevinc, S., SiSli Etfal Hastanesi.., Jun 2022 Favors favipiravir Favors lopinavir/ri..

Favipiravir Experience in COVID-19 Patients at a Tertiary Center Intensive Care Unit

Acar Sevinc, S., SiSli Etfal Hastanesi Tip Bulteni / The Medical Bulletin of Sisli Hospital, doi:10.14744/SEMB.2021.35902, NCT04645433
Jun 2022  
  Source   PDF   All   Meta
Retrospective 100 ICU patients in Turkey, showing improved survival with favipiravir vs. lopinavir/ritonavir.
This study is excluded in the after exclusion results of meta analysis: very late stage, ICU patients.
risk of death, 16.2% lower, RR 0.84, p = 0.38, treatment 57 of 85 (67.1%), control 12 of 15 (80.0%), NNT 7.7.
risk of mechanical ventilation, 10.3% lower, RR 0.90, p = 0.75, treatment 61 of 85 (71.8%), control 12 of 15 (80.0%), NNT 12.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Acar Sevinc et al., 28 Jun 2022, retrospective, Turkey, peer-reviewed, mean age 65.6, 1 author, study period 10 March, 2020 - 10 May, 2020, this trial compares with another treatment - results may be better when compared to placebo, trial NCT04645433 (history). Contact:
This PaperFavipiravirAll
Favipiravir Experience in COVID-19 Patients at a Tertiary Center Intensive Care Unit
C Ovid-19, Sultan Acar Sevinc, Ayse Surhan Cin, Nermin Balta Basi, Seyhan Metin, Tugba Yucel, Serkan Islamoglu, Mustafa Altinay, Haci Mustafa Ozdemir, Etfal Sisli, Hospital
SiSli Etfal Hastanesi Tip Bulteni / The Medical Bulletin of Sisli Hospital, doi:10.14744/semb.2021.35902
is the disease caused by severe acute respira- tory syndrome coronavirus 2 (SARS-CoV-2) infection and may present in different clinical scenarios: About 80% of patients present with mild, 13.8% present with severe disease, and 6.1% with critical disease. [1] According to the guidelines published by the Ministry of Health in Turkey, patients with severe and critical disease were advised to be admitted to intensive care unit (ICU). [2] Turkey diagnosed Objectives: The aim of this study was to compare intensive care unit (ICU) and overall hospital mortality in patients treated with favipiravir and lopinavir-ritonavir for COVID-19. Methods: Data were collected retrospectively between March 10 and May 10, 2020, from patients' records admitted to ICU due to COVID-19. Laboratory data, clinical characteristics, ICU and hospital mortality, ICU and hospital length of stay were compared in patients treated with favipiravir and lopinavir-ritonavir. Results: A total of 100 patients' data were investigated. Favipiravir was used as the treatment for 85% of patients, with the rest treated with lopinavir-ritonavir. Clinical and laboratory data of both antiviral treatment groups were similar. Length of hospital stay was 16 (9-24) days with favipiravir and 8.5 (5-12.5) days with lopinavir-ritonavir (p=0.002). Length of ICU stay for favipiravir and lopinavir-ritonavir groups were 8 (5-15) days and 4 (3-9) days, respectively (p=0.011). ICU mortality was 65.9% for the favipiravir and 80% for lopinavir-ritonavir (p=0.002). Hospital mortality for favipiravir and lopinavir-ritonavir was 67.1% and 80%, respectively (p=0.001). Conclusion: The mortality in patients treated with favipiravir was less than patients treated with lopinavir-ritonavir. Favipiravir needs more attention and trials for its effect to be confirmed.
Bhatraju, Ghassemieh, Nichols, Kim, Jerome et al., Covid-19 in critically Ill patients in the Seattle regioncase series, N Engl J Med, doi:10.1056/NEJMoa2004500
Cai, Yang, Liu, Chen, Shu et al., Experimental treatment with favipiravir for COVID-19: An open-label control study, Engineering, doi:10.1016/j.eng.2020.03.007
Chen, Liang, Li, Guo, Fei et al., Mental health care for medical staff in China during the COVID-19 outbreak, Lancet Psychiatry, doi:10.1016/S2215-0366(20)30078-X
Du, Chen, Favipiravir: Pharmacokinetics and concerns about clinical trials for 2019-nCoV infection, Clin Pharmacol Ther, doi:10.1002/cpt.1844
Furuta, Gowen, Takahashi, Shiraki, Smee et al., Favipiravir (T-705), a novel viral RNA polymerase inhibitor, Antiviral Res, doi:10.1016/j.antiviral.2013.09.015
Grasselli, Zangrillo, Zanella, Antonelli, Cabrini et al., Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy, JAMA, doi:10.1001/jama.2020.5394
Ilhan, Altuntas, Optimum management of COVID-19 in the geriatric population: The need for a comprehensive assessment
Kupferschmidt, Cohen, WHO launches global megatrial of the four most promising coronavirus treatments
Mitra, Fergusson, Lloyd-Smith, Wormsbecker, Foster et al., Baseline characteristics and outcomes of patients with COVID-19 admitted to intensive care units in Vancouver, Canada: a case series, CMAJ, doi:10.1503/cmaj.200794
Pascarella, Strumia, Piliego, Bruno, Buono et al., COVID-19 diagnosis and management: a comprehensive review, J Intern Med, doi:10.1111/joim.13091
Shiraki, Daikoku, Favipiravir, an anti-influenza drug against life-threatening RNA virus infections, Pharmacol Ther, doi:10.1016/j.pharmthera.2020.107512
Stringer, Puskarich, Kenes, Dickson, COVID-19: The uninvited guest in the intensive care unit -implications for pharmacotherapy, Pharmacotherapy, doi:10.1002/phar.2394
Wang, Hu, Hu, Zhu, Liu et al., Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirusinfected pneumonia in Wuhan, China, JAMA, doi:10.1001/jama.2020.1585
Yamamoto, Matsuyama, Hoshino, Yamamoto, Nelfinavir inhibits replication of severe acute respiratory syndrome coronavirus 2 in vitro, bioRxiv, doi:10.1101/2020.04.06.026476
Zheng, Sun, Xu, Pan, Zhang et al., Clinical characteristics of 34 COVID-19 patients admitted to intensive care unit in Hangzhou, China, J Zhejiang Univ Sci B, doi:10.1631/jzus.B2000174
{ 'DOI': '10.14744/semb.2021.35902', 'ISSN': ['1302-7123'], 'URL': '', 'author': [{'affiliation': [], 'family': 'Acar Sevinc', 'given': 'Sultan', 'sequence': 'first'}], 'container-title': 'SiSli Etfal Hastanesi Tip Bulteni / The Medical Bulletin of Sisli Hospital', 'container-title-short': 'Sisli Etfal', 'content-domain': {'crossmark-restriction': False, 'domain': []}, 'created': {'date-parts': [[2021, 9, 22]], 'date-time': '2021-09-22T07:37:37Z', 'timestamp': 1632296257000}, 'deposited': { 'date-parts': [[2021, 9, 22]], 'date-time': '2021-09-22T07:37:39Z', 'timestamp': 1632296259000}, 'indexed': {'date-parts': [[2022, 3, 29]], 'date-time': '2022-03-29T14:01:08Z', 'timestamp': 1648562468806}, 'is-referenced-by-count': 0, 'issued': {'date-parts': [[2021]]}, 'member': '5966', 'original-title': [], 'prefix': '10.14744', 'published': {'date-parts': [[2021]]}, 'published-online': {'date-parts': [[2021]]}, 'published-print': {'date-parts': [[2021]]}, 'publisher': 'Kare Publishing', 'reference-count': 0, 'references-count': 0, 'relation': {}, 'resource': {'primary': {'URL': ''}}, 'score': 1, 'short-title': [], 'source': 'Crossref', 'subtitle': [], 'title': 'Favipiravir Experience in COVID-19 Patients at a Tertiary Center Intensive Care Unit', 'type': 'journal-article'}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop